X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Lupin: Generics booster - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • May 21, 2002

    Lupin: Generics booster

    Lupin Ltd. has ended FY02 with 6% growth in sales and an encouraging 48% jump in PBT. Net profit however, grew by 20% on account of new accounting policy on deferred taxation. The growth in sales was fuelled by higher export growth. Operating margins jumped by more than 310 basis points. During the year, the company initiated several measures to achieve roboust growth in exports and push R&D as a key area of growth, going forward.

    (Rs m) FY01 FY02 % Change
    Sales 9,029 9,569 6.0%
    Other Income 86 85 -1.6%
    Expenditure 7,682 7,836 2.0%
    Operating Profit (EBDIT) 1,347 1,733 28.7%
    Operating Profit Margin (%) 14.9% 18.1%  
    Interest 597 622 4.2%
    Depreciation 185 232 25.1%
    Profit before Tax 650 964 48.2%
    Tax 50 242 384.0%
    Profit after Tax/(Loss) 600 722 20.3%
    Net profit margin (%) 6.6% 7.5%  
    No. of Shares (m) 40.1 40.1  
    Diluted Earnings per share 15.0 17.7  
    P/E (at current price) 6.1  

    The highlight of the results was a 34% rise in exports on the back of a sharp rise in contribution from generics exports to US and European markets, which increased by more than 6 fold. Formulations business recorded a growth of 3%. While export formulations registered a drop of more than 44% (though on a smaller base), domestic formulations growth was 6%. Domestic formulations sales were affected by downward revision in prices of rifampicin formulations on account of the new DPCO order.

    Particulars FY01 FY02 % Change
    Generics 93 728 680.2%
    API/ Bulk Drugs 4,718 4,488 -4.9%
    Formulations 4,163 4,283 2.9%
    Others 54 70 27.9%
      9,029 9,569 6.0%

    The company launched several new products during the year particularly in the cardiovascular, cephalosporins and anti-TB segments. In the Cephalosporin segment, the company is steadily consolidating market share with the introduction of new products at the same time focusing upon its current product portfolio. The cephalosporin segment registered a growth of around 8% during the year. It has launched 15 products during the year. Lupin plans to introduce 70-80 products in the span of 3 years, which should reduce its dependence on the anti-TB segment. With new product launches, the cardiovascular segment registered a 50% growth over the last year.

    Exports now contribute around 32% (up from 24% for 9m FY02) to the company's total turnover. Going forward, cephalosporins would be a key focus area for exports. The company intends to explore the partnership route to enter the generic market by tieing up with large generic companies in the US. In the generic business, the company has tied up with three generic marketing companies viz, Merck Generics, ABP and Apcotex. Lupin has already started supplying Cefotaxime and Cefuroxime Axetil in the API form to its marketing alliance in the US. Currently, Ranbaxy has marketing exclusivity for Cefuroxime Axetil in the US and Apcotex, Lupin's partner is expected to start marketing the drug by July'02 this year. At least till mid 2003, Apcotex is expected to be the sole generic competitor to Ranbaxy and thus, the order size for bulk Cefuroxime is expected to provide significant contribution to Lupin in the current year.

    The company has applied for 2 ANDA's (Abbreviated New Drug Application) with the US FDA for Ceftriaxone injection and Cefotaxime injection and it claims to have 'first to file' status on the former. Lupin plans to file 6-7 ANDA's for the US markets this year, with a target of creating a product basket of 25 products over 3 years.

    Lupin has now recognized R&D as a key thrust area. The company has established a state-of-the-art R&D centre spread over an area of 19 acres at Pune. The research activity of the company is focused in such a manner to provide solutions to both immediate and post 2005 research requirements. The company now spends almost 5% of its total revenues on research. Lupin has 6 molecules in the pipeline, both on NCE and NDDS platform. All molecules are in early pre-clinical stages and it would take time (atleast late 2003) before one can expect revenues from out licensing.

    At the current market price of Rs 108, the stock is trading at 6x its earnings for FY02. The current acceleration in its research iniatitives, sales and margins growth and breakthrough in the generics business are expected to prove as good triggers for the stock in the near term. The stock is also attractively priced when compared to its peers. However, a high capital gearing ratio (1.6x approx) is one of the key areas of concern. Debt burden of the company has jumped to Rs 622 m eating away more than one third of its operating profits. Moreover, the capital structure of the company also has significant preference shares, which carries a fixed dividend burden.

     

     

    Equitymaster requests your view! Post a comment on "Lupin: Generics booster". Click here!

      
     

    More Views on News

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

    May 29, 2017

    Currency fluctuation and one time provision impacts operating margins.

    Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    LUPIN LTD SHARE PRICE


    Aug 21, 2017 (Close)

    TRACK LUPIN LTD

    • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    LUPIN LTD - ALKEM LABORATORIES COMPARISON

    Compare Company With Charts

    COMPARE LUPIN LTD WITH

    MARKET STATS